Optical coherence tomography for examining retina in patients with HIV/TB coinfection
DOI: 10.32364/2311-7729-2022-22-1-23-29
E.A. Burylova, A.P. Demin, S.N. Skornyakov, E.V. Sabadash
Ural Scientific Research Institute of Phtysiopulmonology – Branch of the National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ekaterinburg, Russian Federation
Aim: to assess the retina (including peripapillary retinal nerve fiber layer/RNFL and retinal vessel diameter) in patients with tuberculosis (TB) or HIV/TB coinfection in the lack of abnormalities detected by standard eye exam using optical coherence tomography (OCT).
Patients and Methods: all patients were divided into three groups. Group 1 (n=19) included patients with HIV/TB coinfection. Group 2 (n=18) included patients with pulmonary and extrapulmonary TB. Group 3 (n=20) included healthy volunteers (controls). All patients underwent standard eye exam and OCT (iVue-100 v3.2, Optovue, USA) to measure peripapillary RNFL thickness, central macular thickness, and the first-order retinal vessel diameter (eight vessels).
Results: OCT demonstrated greater peripapillary RNFL thickness in the nasal sector (by 13.4–18.3%) and central macular thickness (by 4.0–7.5%), narrowing of retinal arteries, and enlargement of veins (predominantly temporal). These patterns may illustrate retinal microcirculation in the setting of a pathological condition (HIV/TB, including highly active antiretroviral therapy [HAART]) and be a harbinger of further abnormalities of ocular structures and central nervous system.
Conclusion: OCT identifies changes in vessel diameter, central macular thickness, and peripapillary RFNL thickness before visual disturbances in preclinical eye changes in patients with HIV/TB coinfection.
Keywords: HIV, tuberculosis, optical coherence tomography, calipermetry, retina.
For citation: Burylova E.A., Demin A.P., Skornyakov S.N., Sabadash E.V. Optical coherence tomography for examining retina in patients with HIV/TB coinfection. Russian Journal of Clinical Ophthalmology. 2022;22(1):23–29 (in Russ.). DOI: 10.32364/2311-7729-2022-22-1-23-29.
About the authors:
Elena A. Burylova — C. Sc. (Med.), leading researcher, Group of Scientific Research Coordination, ophthalmologist; ORCID iD 0000-0002-4440-4686.
Aleksey P. Demin — ophthalmologist, Clinical Diagnostic Department; ORCID iD 0000-0003-2053-2103.
Sergey N. Skornyakov — Dr. Sc. (Med.), Head of Scientific Clinical Department; ORCID iD 0000-0003-0366-9634.
Elena V. Sabadash — C. Sc. (Med.), senior researcher, Scientific Clinical Department; ORCID iD 0000-0003-4951-7708.
Ural Scientific Research Institute of Phtysiopulmonology – Branch of the National Medical Research Center of Phthisiopulmonology and Infectious Diseases, 50, 22nd Pats’ezd str., Ekaterinburg, 620039, Russian Federation.
Contact information: Elena A. Burylova, e-mail: science@urniif.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 07.09.2021.
2. Solonko I.I., Gurevich G.L., Skryagina E.M., Dyusmikeeva M.I. Extrapulmonary tuberculosis: clinical epidemiological characteristics and diagnostics. Tuberculosis and Lung Diseases. 2018;96(6):22–28 (in Russ.). DOI: 10.21292/2075-1230-2018-96-6-22-28.
3. Stewart М.W. Ophthalmologic Disease in HIV Infection: Recent Changes in Pathophysiology and Treatment. Curr Infect Dis Rep. 2017;19(12):47. DOI: 10.1007/s11908-017-0602-9.
4. Skornyakov S.N., Korotkih S.A., Demin A.P. et al. Modern features of visual organ damage in patients with AIDS and tuberculosis. Medicinskij al’yans. 2015;1:153–154 (in Russ.).
5. Testi I., Mahajan S., Agrawal R. et al. Management of Intraocular Infections in HIV. Ocul Immunol Inflam. 2020;28(7):1099–1108. DOI: 10.1080/09273948.2020.1727533.
6. Holland G.N., Van Natta M.L., Goldenberg D.T. et al. Relationship between opacity of cytomegalovirus retinitis lesion borders and severity of immunodeficiency among people with AIDS. Invest Ophthalmol Vis Sci. 2019;60:1853–1862. DOI: 10.1167/iovs.18-26517.
7. Schaftenaar E., Khosa N.S., Baarsma G.S. et al. HIV-infected individuals on long-term antiretroviral therapy are at higher risk for ocular disease. Epidemiol Infect. 2017;145:2520–2529. DOI: 10.1017/S0950268817000978.
8. Singh S.R., Dogra M., Kaur S. et al. Spectrum of Newly Diagnosed Cytomegalovirus Retinitis in a Developing Country in the HAART Era. Ocul Immunol Inflam. 2020;28(1):119–125. DOI: 10.1080/09273948.2018.1538460.
9. Rothova A., Hajjaj A., Joeri de Hoog et al. Uveitis causes according to immune status of patients. Acta Ophthalmol. 2019;97:53–59. DOI: 10.1111/aos.13877.
10. Agarwal A., Singh R., Sharma A. et al. Ocular Manifestations in Patients with Human Immunodeficiency Virus Infection in the Pre-HAART Versus the HAART Era in the North Indian Population. Ocul Immunol Inflam. 2017;25(3):396–404. DOI: 10.3109/09273948.2015.1133837.
11. Thorne J.E., Jabs D.A., Kempen J.H. et al. Causes of Visual Acuity Loss among Patients with AIDS and Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy. Ophthalmology. 2006;113(8):1441–1445. DOI: 10.1016/j.ophtha.2006.03.022.
12. Demirkaya N., Wit F., Schlingemann R., Verbraak F. Neuroretinal degeneration in HIV patients without opportunistic ocular infections in the cART era. AIDS Patient Care STDs. 2015;29(10):519–532. DOI: 10.1089/apc.2015.0091.
13. Solages A., Vita J.A., Thornton D.J. et al. Endothelial function in HIV-infected persons. Clin Infect Dis. 2006;42:1325–1332. DOI: 10.1086/503261.
14. Faria E., Arantes T.E., Garcia C.R. et al. Structural and functional assessment in HIV-infected patients using optical coherence tomography and frequency doubling technology perimetry. AJO. 2010;149:571–576.e2. DOI: 10.1016/j.ajo.2009.11.026.
15. Lambrozo B., Rispoli M. OKT of the retina. Method of analysis and interpretation. M.: Aprel; 2012 (in Russ.).
16. Optical coherence tomography in the diagnosis of the eye disease. Shchuko A.G., Malysheva V.V., eds. M.: GEOTAR-Media; 2010 (in Russ.).
17. Katargina L.A., Ryabcev D.I., Kogoleva L.V. Method of calibrometry of retinal vessels of the first order using spectral optical coherence tomography. Patent RF № 2456909/2012 (in Russ.).
18. Matukhina E.N. The use of bromfenac in ophthalmic practice (literature review). Ophthalmology. 2021;18(4):784–790 (in Russ.). DOI: 10.18008/1816-5095-2021-4-784-7.
19. Rho D.S., Soll S.M., Markovitz B.J. Bromfenac 0,09% versus diclofenac sodium 0,1% versus ketorolac tromethamine 0,5% in the treatment of acute pseudophakic cystoid macular edema. Invest Ophthalmol Vis Sci. 2006;47:5211.
20. Baklayan G.A., Patterson H.M., Song C.K. et al. 24-hour evaluation of the ocular dis- tribution of (14) C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24:392–398. DOI: 10.1089/jop.2007.0082.
21. Donnenfeld E.D., Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin. 2006;46(4):21–40. DOI: 10.1097/01.iio.0000212134.83513.11.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
